<DOC>
	<DOCNO>NCT02739217</DOCNO>
	<brief_summary>This Phase 2 , single-centre , single-arm , open-label study safety , tolerability , effect biomarkers PBI-4050 subject Alström syndrome treatment duration 24 week .</brief_summary>
	<brief_title>Safety Tolerability PBI-4050 Its Effects Biomarkers Subjects With Alström Syndrome</brief_title>
	<detailed_description>This Phase 2 , single-centre , single-arm , open-label study safety , tolerability , effect biomarkers PBI-4050 subject Alström syndrome . Approximately 18 subject enrol . The duration study participation approximately 34 week subject comprise 9 site visit telephone contact visit .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Alstrom Syndrome</mesh_term>
	<criteria>Inclusion Criteria : Subject 16 year age old screening . Subject sign informed consent . Subject documented diagnosis Alström syndrome Subject diabetes treatment receive antidiabetic agent ( ) minimum 1 month screening . Subject able willing selfmonitor blood glucose level home obtain adequate assistance care giver . Subject body mass index ( BMI ) least 25 kg/m2 screening . Female subject childbearing potential must negative serum pregnancy test screen agree use adequate birth control screen throughout study 30 day last Investigational Medicinal Product ( IMP ) administration . If male subject vasectomize least 6 month screen partner woman childbearing potential , must willing use acceptable contraceptive method throughout study 30 day last IMP administration . Subject recent ongoing infection require systemic treatment antiinfective agent within 30 day screen . Subject least two documented episode severe hypoglycaemia within 12 month screen Subject uncontrolled hypertension BP &gt; 170/100 mmHg determine screen . Subject alanine transaminase ( ALT ) aspartate transaminase ( AST ) level ≥ 5 × upper limit normal ( ULN ) screening . Subject currently use weight loss medication screen . Subjects may rescreened stop weight loss medication period least 5 halflives . Subject use strong inducer inhibitor cytochrome P450 ( CYP ) 3A isozyme within 30 day prior first study drug administration . Subject history chronic alcohol substance abuse determine screen . Woman pregnant , breastfeeding , plan pregnancy course study determine screen . Subject condition , investigator 's opinion , likely interfere study conduct compliance</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>